表紙
市場調查報告書
商品編碼
999765

非專利可注射的全球市場:產業趨勢,市場佔有率·規模·成長率·機會及預測(2021年∼2026年)

Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日期: | 出版商: IMARC Services Private Limited | 英文 145 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

由於非專利注射的好處,各國政府都在支持其生產。此外,越來越多的藥品短缺,尤其是在美國,許多重磅炸彈藥品的專利到期,人口老齡化以及慢性病和與生活方式有關的疾病的患病率上升,也是推動市場增長的因素。到2020年,全球非專利可注射市場規模將達到338.2億美元,並有望在2021年至2026年間呈現強勁增長。

本報告提供全球非專利可注射市場的相關調查,提供產業趨勢,市場預測,主要地區·治療領域·容器·各流通管道的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 序文

第2章 範圍和調查方法

第3章 摘要整理

第4章 簡介

第5章 全球學名藥市場

  • 市場概要
  • 市場實際成果
  • 各地區的市場區隔
  • 主要企業

第6章 各藥物輸送市場

  • 口服
  • 注射劑
  • 皮膚/局部
  • 吸入器

第7章 全球非專利可注射市場

  • 市場概要
  • 市場效能
  • COVID-19的影響
  • 各地區的市場區隔
  • 各治療領域的市場區隔
  • 容器別的市場區隔
  • 各流通管道的市場區隔
  • SWOT分析
    • 概要
    • 優勢
    • 弱點
    • 市場機會
    • 威脅
  • 價值鏈分析
  • 波特的五力分析
  • 主要的市場成長要素與成功因素

第8章 全球非專利可注射市場:主要地區市場

  • 北美
  • 歐洲
  • 亞洲
  • 南美
  • 中東·非洲

第9章 各治療領域的市場

  • 腫瘤學
  • 麻醉
  • 抗感染藥
  • 非口服營養
  • 心臟血管

第10章 容器別的市場

  • 管瓶
  • 安瓿
  • 預混合料
  • 預填充式注射器

第11章 各流通管道的市場

  • 醫院
  • 零售藥局

第12章 世界的非專利可注射市場:競爭情形

  • 競爭結構
  • 各主要企業市場區隔

第13章 非專利可注射的製造流程

  • 產品概要
  • 詳細的流程
  • 涉及各種類型的單位行動
  • 物質收支和原料的必要條件

第14章 計劃詳細內容,必要條件,及相關的成本

  • 土地的必要條件與支出
  • 建設必要條件與支出
  • 工廠的機器
  • 機器的印象
  • 原料的必要條件與支出
  • 包裝必要條件與支出
  • 運輸必要條件與支出
  • 公共事業的必要條件與支出
  • 人力資源的必要條件與支出
  • 其他設備投資

第15章 貸款和財政支援

第16章 計劃的經濟學

  • 計劃的資本成本
  • 技術經濟參數
  • 供應鏈的各種各樣的層級的產品的價格設定和保證金
  • 課稅和折舊免稅額
  • 收益預測
  • 支出預測
  • 財務分析
  • 利益分析

第17章 主要企業的簡介

  • Hospira (Pfizer)
    • 企業概要
    • 產品系列
    • 財務
    • SWOT分析
  • Fresenius Kabi
    • 企業概要
    • 產品系列
    • 財務
    • SWOT分析
  • Hikma
    • 企業概要
    • 產品系列
    • 財務
    • SWOT分析
  • Sandoz (Novartis)
    • 企業概要
    • 產品系列
    • 財務
    • SWOT分析
  • Sagent
    • 企業概要
    • 產品系列
    • 財務
    • SWOT分析
  • Sanofi
    • 企業概要
    • 產品系列
    • 財務
    • SWOT分析
  • Baxter
    • 企業概要
    • 產品系列
    • 財務
    • SWOT分析
目錄
Product Code: SR1020B151_Report

Generic injectables are bio-equivalents of their branded counterparts which are not protected by drug patents. They are as safe and effective as the innovator drugs since they have similar active ingredient, dosage, strength, quality, form, etc. Although the manufacturing of generic injectables is complex, their R&D cycle is cheaper and shorter. Unlike branded drug manufacturers who spend millions of dollars on R&D and marketing, generic drug manufacturers do not require such investments. Moreover, the number of competitors in the generic injectables market is lower as compared to oral generics, resulting in limited price erosion and significantly higher profit margins.

Owing to the advantages offered by generic injectables, governments in various countries are supporting their manufacture. Additionally, an increase in drug shortages, especially in the US, along with patent expiry of a number of blockbuster drugs, aging population and rising prevalence of chronic as well as lifestyle diseases represent some of the other factors driving the growth of the market. According to IMARC Group's latest report titled, "Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026", the global generic injectables market reached a value of US$ 33.82 Billion in 2020. Looking forward, IMARC Group expects the market to exhibit strong growth during 2021-2026.

The report has segmented the market on the basis of therapeutic area as oncology, anaesthesia, anti-infectives, parenteral nutrition, cardiovascular and others. Currently, the oncology segment accounts for the majority of the market share. Further, the report has segmented the market on the basis of distribution channels covering hospitals and retail pharmacy stores. Among these, hospitals account for the largest market share. On a regional-basis, the report covers North America, Europe, Asia, Latin America, and Middle East and Africa. North America represents the largest region, accounting for more than a half of the global market. The report has also analysed the competitive landscape of the market with some of the key players being Hospira (Pfizer), Fresenius Kabi, Hikma, Sandoz (Novartis), Sagent, Sanofi and Baxter.

This report provides a deep insight into the global generic injectables industry covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. The report also provides a comprehensive analysis for setting up a generic injectables manufacturing plant. The study analyses the processing and manufacturing requirements, project cost, project funding, project economics, expected returns on investment, profit margins, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the global generic injectables industry in any manner.

Key Questions Answered in This Report:

  • How has the generic injectables market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global generic injectables industry?
  • What are the key regional markets in the global generic injectables industry?
  • What are the price trends of generic injectables?
  • What are the various stages in the value chain of the generic injectables industry?
  • What are the key driving factors and challenges in the generic injectables industry?
  • What is the structure of the global generic injectables industry and who are the key players?
  • What is the degree of competition in the global generic injectables industry?
  • What are the profit margins in the generic injectables industry?
  • What are the key requirements for setting up a generic injectables manufacturing plant?
  • How are generic injectables manufactured?
  • What are the various unit operations involved in a generic injectables manufacturing plant?
  • What is the total size of land required for setting up a generic injectables manufacturing plant?
  • What are the machinery requirements for setting up a generic injectables manufacturing plant?
  • What are the raw material requirements for setting up a generic injectables manufacturing plant?
  • What are the packaging requirements for generic injectables?
  • What are the transportation requirements for generic injectables?
  • What are the utility requirements for setting up a generic injectables manufacturing plant?
  • What are the manpower requirements for setting up a generic injectables manufacturing plant?
  • What are the infrastructure costs for setting up a generic injectables manufacturing plant?
  • What are the capital costs for setting up a generic injectables manufacturing plant?
  • What are the operating costs for setting up a generic injectables manufacturing plant?
  • What will be the income and expenditures for a generic injectables manufacturing plant?
  • What is the time required to break-even?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Generic Drug Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Market Breakup by Region
  • 5.4 Market Forecast
  • 5.5 Major Players

6 Global Generic Drug Delivery Market

  • 6.1 Oral
  • 6.2 Injectables
  • 6.3 Dermal/Topical
  • 6.4 Inhalers

7 Global Generic Injectables Market

  • 7.1 Market Overview
  • 7.2 Market Performance
  • 7.3 Impact of COVID-19
  • 7.4 Market Breakup by Region
  • 7.5 Market Breakup by Therapeutic Area
  • 7.6 Market Breakup by Container
  • 7.7 Market Breakup by Distribution Channel
  • 7.8 Market Forecast
  • 7.9 SWOT Analysis
    • 7.9.1 Overview
    • 7.9.2 Strengths
    • 7.9.3 Weaknesses
    • 7.9.4 Opportunities
    • 7.9.5 Threats
  • 7.10 Value Chain Analysis
  • 7.11 Porter's Five Forces Analysis
    • 7.11.1 Overview
    • 7.11.2 Bargaining Power of Buyers
    • 7.11.3 Bargaining Power of Suppliers
    • 7.11.4 Degree of Competition
    • 7.11.5 Threat of New Entrants
    • 7.11.6 Threat of Substitutes
  • 7.12 Key Market Drivers and Success Factors

8 Global Generic Injectables Market: Performance of Key Regions

  • 8.1 North America
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Europe
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Asia
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market by Therapeutic Area

  • 9.1 Oncology
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Anaesthesia
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Anti-infectives
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Parenteral Nutrition
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Cardiovascular
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market by Container

  • 10.1 Vials
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Ampoules
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Premix
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Prefilled Syringes
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market by Distribution Channel

  • 11.1 Hospitals
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Retail Pharmacy
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast

12 Global Generic Injectable Market: Competitive Landscape

  • 12.1 Competitive Structure
  • 12.2 Market Breakup by Key Players

13 Generic Injectable Manufacturing Process

  • 13.1 Product Overview
  • 13.2 Detailed Process Flow (Injectable)
  • 13.3 Various Types of Unit Operations Involved
  • 13.4 Mass Balance and Raw Material Requirements

14 Project Details, Requirements and Costs Involved

  • 14.1 Land Requirements and Expenditures
  • 14.2 Construction Requirements and Expenditures
  • 14.3 Plant Machinery
  • 14.4 Machinery Pictures
  • 14.5 Raw Material Requirements and Expenditures
  • 14.6 Packaging Requirements and Expenditures
  • 14.7 Transportation Requirements and Expenditures
  • 14.8 Utility Requirements and Expenditures
  • 14.9 Manpower Requirements and Expenditures
  • 14.10 Other Capital Investments

15 Loans and Financial Assistance

16 Project Economics

  • 16.1 Capital Cost of the Project
  • 16.2 Techno-Economic Parameters
  • 16.3 Product Pricing and Margins Across Various Levels of the Supply Chain
  • 16.4 Taxation and Depreciation
  • 16.5 Income Projections
  • 16.6 Expenditure Projections
  • 16.7 Financial Analysis
  • 16.8 Profit Analysis

17 Key Player Profiles

  • 17.1 Hospira (Pfizer)
    • 17.1.1 Company Overview
    • 17.1.2 Product Portfolio
    • 17.1.3 Financials
    • 17.1.4 SWOT Analysis
  • 17.2 Fresenius Kabi
    • 17.2.1 Company Overview
    • 17.2.2 Product Portfolio
    • 17.2.3 Financials
    • 17.2.4 SWOT Analysis
  • 17.3 Hikma
    • 17.3.1 Company Overview
    • 17.3.2 Product Portfolio
    • 17.3.3 Financials
    • 17.3.4 SWOT Analysis
  • 17.4 Sandoz (Novartis)
    • 17.4.1 Company Overview
    • 17.4.2 Product Portfolio
    • 17.4.3 Financials
    • 17.4.4 SWOT Analysis
  • 17.5 Sagent
    • 17.5.1 Company Overview
    • 17.5.2 Product Portfolio
    • 17.5.3 Financials
    • 17.5.4 SWOT Analysis
  • 17.6 Sanofi
    • 17.6.1 Company Overview
    • 17.6.2 Product Portfolio
    • 17.6.3 Financials
    • 17.6.4 SWOT Analysis
  • 17.7 Baxter
    • 17.7.1 Company Overview
    • 17.7.2 Product Portfolio
    • 17.7.3 Financials
    • 17.7.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Generic Drug Market: Sales Value Trends (in Billion US$), 2015 - 2020
  • Figure 2: Global: Generic Drug Market: Breakup by Region (in %), 2020
  • Figure 3: Global: Generic Drug Market Forecast: Sales Value Trends (in Billion US$), 2021-2026
  • Figure 4: Global: Generic Drug Delivery Market: Oral (in Million US$), 2015, 2020 & 2026
  • Figure 5: Global: Generic Drug Delivery Market: Injectables (in Million US$), 2015, 2020 & 2026
  • Figure 6: Global: Generic Drug Delivery Market: Dermal/Topical (in Million US$), 2015, 2020 & 2026
  • Figure 7: Global: Generic Drug Delivery Market: Inhalers (in Million US$), 2015, 2020 & 2026
  • Figure 8: Global: Generic Injectables Market: Sales Value Trends (in Billion US$), 2015 - 2020
  • Figure 9: Global: Generic Injectables Market: Breakup by Region (in %), 2020
  • Figure 10: Global: Generic Injectables Market: Breakup by Therapeutic Area (in %), 2020
  • Figure 11: Global: Generic Injectables Market: Breakup by Container (in %), 2020
  • Figure 12: Global: Generic Injectables Market: Breakup by Distribution Channels (in %), 2020
  • Figure 13: Global: Generic Injectables Market Forecast: Sales Value Trends (in Billion US$), 2021-2026
  • Figure 14: Global: Generic Injectables Industry: SWOT Analysis
  • Figure 15: Global: Generic Injectables Industry: Value Chain Analysis
  • Figure 16: Global: Generic Injectables Industry: Porter's Five Forces Analysis
  • Figure 17: North America: Generic Injectable Market (in Million US$), 2015, 2020 & 2026
  • Figure 18: Europe: Generic Injectable Market (in Million US$), 2015, 2020 & 2026
  • Figure 19: Asia: Generic Injectable Market (in Million US$), 2015, 2020 & 2026
  • Figure 20: Latin America: Generic Injectable Market (in Million US$), 2015, 2020 & 2026
  • Figure 21: Middle East and Africa: Generic Injectable Market (in Million US$), 2015, 2020 & 2026
  • Figure 22: Global: Generic Injectable (Oncology) Market: Value Trends (in Million US$), 2015 & 2020
  • Figure 23: Global: Generic Injectable (Oncology) Market Forecast: Value Trends (in Million US$), 2021-2026
  • Figure 24: Global: Generic Injectable (Anaesthesia) Market: Value Trends (in Million US$), 2015 & 2020
  • Figure 25: Global: Generic Injectable (Anaesthesia) Market Forecast: Value Trends (in Million US$), 2021-2026
  • Figure 26: Global: Generic Injectable (Anti-infectives) Market: Value Trends (in Million US$), 2015 & 2020
  • Figure 27: Global: Generic Injectable (Anti-infectives) Market Forecast: Value Trends (in Million US$), 2021-2026
  • Figure 28: Global: Generic Injectable (Parenteral Nutrition) Market: Value Trends (in Million US$), 2015 & 2020
  • Figure 29: Global: Generic Injectable (Parenteral Nutrition) Market Forecast: Value Trends (in Million US$), 2021-2026
  • Figure 30: Global: Generic Injectable (Cardiovascular) Market: Value Trends (in Million US$), 2015 & 2020
  • Figure 31: Global: Generic Injectable (Cardiovascular) Market Forecast: Value Trends (in Million US$), 2021-2026
  • Figure 32: Global: Generic Injectable (Vials) Market: Value Trends (in Million US$), 2015 & 2020
  • Figure 33: Global: Generic Injectable (Vials) Market Forecast: Value Trends (in Million US$), 2021-2026
  • Figure 34: Global: Generic Injectable (Ampoules) Market: Value Trends (in Million US$), 2015 & 2020
  • Figure 35: Global: Generic Injectable (Ampoules) Market Forecast: Value Trends (in Million US$), 2021-2026
  • Figure 36: Global: Generic Injectable (Premix) Market: Value Trends (in Million US$), 2015 & 2020
  • Figure 37: Global: Generic Injectable (Premix) Market Forecast: Value Trends (in Million US$), 2021-2026
  • Figure 38: Global: Generic Injectable (Prefilled Syringes) Market: Value Trends (in Million US$), 2015 & 2020
  • Figure 39: Global: Generic Injectable (Prefilled Syringes) Market Forecast: Value Trends (in Million US$), 2021-2026
  • Figure 40: Global: Generic Injectable Market: Sales through Hospitals (in Million US$), 2015 & 2020
  • Figure 41: Global: Generic Injectable Market Forecast: Sales through Hospitals (in Million US$), 2021-2026
  • Figure 42: Global: Generic Injectable Market: Sales through Retail Pharmacy (in Million US$), 2015 & 2020
  • Figure 43: Global: Generic Injectable Market Forecast: Sales through Retail Pharmacy (in Million US$), 2021-2026
  • Figure 44: Generic Injectable Manufacturing Process: Conversion Rate of Feedstocks
  • Figure 45: Generic Injectable Manufacturing: Detailed Process Flow
  • Figure 46: Generic Injectable Manufacturing: Production Cost Breakup (in %)
  • Figure 47: Generic Injectable Industry: Profit Margins at Various Levels of the Supply Chain
  • Figure 48: Generic Injectable Manufacturing Plant: Proposed Plant Layout
  • Figure 49: Generic Injectable Manufacturing Plant: Breakup of Capital Costs (in %)

List of Tables

  • Table 1: Global: Generic Drug Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Generic Drug Market Forecast: Breakup by Region, 2021-2026
  • Table 3: Global: Generic Drug Market: Revenues of Key Players (in Million US$), 2019
  • Table 4: Global: Generic Injectables Market: Key Industry Highlights, 2020 and 2026
  • Table 5: Global: Generic Injectables Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 6: Global: Generic Injectables Market Forecast: Breakup by Therapeutic Area (in Million US$), 2021-2026
  • Table 7: Global: Generic Injectables Market Forecast: Breakup by Container (in Million US$), 2021-2026
  • Table 8: Global: Generic Injectables Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
  • Table 9: Generic Injectable Manufacturing Plant: Costs Related to Land and Site Development (in US$)
  • Table 10: Generic Injectable Manufacturing Plant: Costs Related to Civil Works (in US$)
  • Table 11: Generic Injectable Manufacturing Plant: Costs Related to Machinery Unit (in US$)
  • Table 12: Generic Injectable Manufacturing Plant: Raw Material Requirements (Kg/Day) and Expenditures (US$/Kg)
  • Table 13: Generic Injectable Manufacturing Plant: Costs Related to Salaries and Wages (in US$)
  • Table 14: Generic Injectable Manufacturing Plant: Costs Related to Other Capital Investments (in US$)
  • Table 15: Details of Financial Assistance Offered by Financial Institutions
  • Table 16: Generic Injectable Manufacturing Plant: Capital Costs (in US$)
  • Table 17: Generic Injectable Manufacturing Plant: Techno-Economic Parameters (in US$)
  • Table 18: Generic Injectable Manufacturing Plant: Taxation and Depreciation (in US$)
  • Table 19: Generic Injectable Manufacturing Plant: Income Projections (in US$)
  • Table 20: Generic Injectable Manufacturing Plant: Expenditure Projections (in US$)
  • Table 21: Generic Injectable Manufacturing Plant: Cash Flow Analysis Without Considering the Income Tax Liability (in US$)
  • Table 22: Generic Injectable Manufacturing Plant: Cash Flow Analysis on Considering the Income Tax Liability (in US$)
  • Table 23: Generic Injectable Manufacturing Plant: Profit and Loss Account (in US$)